IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Shore, Neal
Stenzl, Arnulf
Pieczonka, Christopher
Klaassen, Zachary
Aronson, William
Karsh, Lawrence
Ryan, Charles
Miskic, Marina
Srinivasan, Shankar
Mohamed, Ateesha
Verholen, Frank
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD34-10
引用
下载
收藏
页码：E586 / E587
页数：2
相关论文
共 50 条
  • [1] Impact of Darolutamide on Local Symptoms in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 11 - 12
  • [2] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1235 - 1246
  • [3] Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Le Berre, Marie-Aude
    Petrenciuc, Oana
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (11): : 1040 - 1049
  • [4] Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2019, 202 (04): : 660 - 661
  • [5] Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
    Appukkuttan, Sreevalsa
    Farej, Ryan
    Miles, LaStella
    Purser, Molly
    Wen, Lonnie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (02): : 166 - 174
  • [6] Re: Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2021, 205 (04): : 1226 - 1227
  • [7] FDA Approves Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 498 - 498
  • [8] ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 2 - 5
  • [9] Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
    Carles, Joan
    Medina-Lopez, Rafael A.
    Puente, Javier
    Gomez-Ferrer, Alvaro
    Nebra, Javier Casas
    Medina, Maria Isabel Saez
    Ribal, Maria J.
    Antolin, Alfredo Rodriguez
    Alvarez-Ossorio, Jose Luis
    Novo, Jose Francisco Suarez
    Agut, Cristina Moretones
    Srinivasan, Shankar
    Ortiz, Jorge
    Fizazi, Karim
    FUTURE ONCOLOGY, 2023, 19 (12) : 819 - 828
  • [10] DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Armstrong, Andrew J.
    Suzuki, Hiroyoshi
    Bailen, James L.
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Khan, Javeed
    Briganti, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17029 - E17029
12345